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Summary 
We have recently developed the technology to identify and characterize the human histocompatibility 
leukocyte antigen (HLA) class I-restricted, CD8 + cytotoxic T lymphocyte (CTL) response to 
hepatitis B virus (HBV)-encoded antigens in patients with acute viral hepatitis. CTL are expanded 
in vitro by stimulation with HBV-derived synthetic peptides and selected by restimulation with 
a panel of HLA-matched stable transfectants  that express the corresponding HBV protein. We 
have recently reported the existence of an HLA-A2-restricted,  CD8 + CTL response to an epitope 
located between residues 18 and 27 of the HBV nucleocapsid core antigen (HBcAg). We now 
report the discovery of a CTL epitope located between HBcAg residues 141 and 151 that completely 
overlaps a critical domain in the viral nucleocapsid protein that is essential for its nuclear localization 
and genome packaging functions as well as processing of the precore protein. The CTL response 
to this epitope is dually restricted by the HLA-A31 and HLA-Aw68 alleles, which, unexpectedly, 
appear to use a common  binding motif  based on the results of alanine substitution and competition 
analysis, and the binding properties of these two alleles predicted from their known primary 
sequence, and from the three-dimensional structure of HLA-Aw68. We have also demonstrated 
that the HBV-specific CTL response to this epitope is polyclonal during acute viral hepatitis, 
since these two restriction elements can present the HBcAg 141-151 epitope to independent CTL 
clones derived from a single patient; and that the CTL response is multispecific,  since HLA-A2- 
restricted and HLA-Aw68-restricted CTL responses  to HBcAg 18-27  and HBcAg 141-151, 
respectively, have been identified to coexist in another patient. The foregoing argue against the 
emergence of CTL escape mutants as a significant  problem during HBV infection, especially 
at this locus, where mutations might be incompatible with viral replication. Finally, our data 
suggest an association between the HBV-specific CTL response and viral clearance, and they have 
implications for the design of immunotherapeutic strategies  to terminate HBV infection in 
chronically infected patients. 
T 
he hepatitis B virus (HBV)  1 is a small hepatotropic en- 
veloped virus with a double-stranded DNA genome (1) 
that causes acute and chronic necroinflammatory liver dis- 
ease and hepatocellular carcinoma (2). The mechanisms respon- 
sible for viral clearance and liver cell injury in HBV infection 
are not well understood. Based on precedent in other viral 
1 Abbreviations used in this paper: HBcAg, hepatitis B core antigen; HBV, 
hepatitis B virus. 
systems, and a limited analysis of the intrahepatic (3-5) and 
PBL (6) response to HBV-encoded antigens, it appears that 
HBV-specific helper and CTL responses may play an impor- 
tant pathogenetic role in this disease. Since the viral nucleo- 
capsid protein is an important target of the CTL response 
to other viruses (7-11), we have begun to examine the HLA 
class I-restricted CTL response to the hepatitis B nucleocapsid 
core antigen (HBcASg) in patients with acute and chronic 
viral hepatitis, type B. 
In a recent series of studies, we demonstrated that ~>90% 
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duce an HLA-A2-restricted, CD8-positive CTL response  to 
a 10-residue epitope that maps between amino acids 18 and 
27 (FLPSDFFPSV) of  HBcAg (12). In contrast, we have shown 
that this response  is not detectable in the peripheral blood 
in HLA-A2-positive patients with chronic hepatitis (13), sug- 
gesting that a vigorous CTL response  to this epitope may 
contribute to viral clearance during HBV infection. 
In the current study, we report the discovery and charac- 
terization of a new CTL epitope, recognized by patients with 
acute viral  hepatitis, that maps to amino acids 141-151 of 
HBcAg (STLPETTVVRR).  CTL recognition of this epi- 
tope is restricted by two independent class I molecules, HLA- 
A31 and HLA-Aw68, and both responses are focused on pre- 
cisely the same 11-residue sequence.  To our knowledge this 
represents the first report that two independent human class 
I molecules can present precisely the same endogenously syn- 
thesized epitope to independently rearranged TCRs. Further- 
more, our data provide insight into the probable antigenic 
peptide binding motifs for these two independent HLA alleles. 
Additionally, together with our previous reports (12-14), the 
current observations suggest that the HLA class I-restricted 
CTL response plays an important role in viral clearance during 
acute HBV infection, and they raise the possibility that specific 
augmentation of this response might lead to viral clearance 
in patients with chronic hepatitis. 
Materials  and Methods 
Patient Population.  Six patients, five  male and one female, with 
acute hepatitis B and nine normal blood donors were studied (Table 
1). The diagnosis of acute hepatitis B was based on standard diag- 
nostic criteria including clinical and biochemical  evidence  of severe 
liver cell  injury with ahnine aminotransferase  (ALT) activity at least 
20-fold higher than the upper limits of normal, together with sero- 
logical evidence  of acute HBV infection, including hepatitis B sur- 
face antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab), 
and the absence of serological  evidence  of infection by the hepatitis 
or hepatitis C viruses (using commercially  available reagents ob- 
tained from Abbot Laboratories, North Chicago, IL). All patients 
recovered completely  from the illness, with normalization of serum 
transaminase and clearance of HBsAg within 4 mo of initial di- 
agnosis. 
Synthetic Peptides, HBV Antigens,  and Tetanus Toxoid.  A panel 
of overlapping synthetic peptides,  10--20 residues long,  corre- 
sponding to the complete HBV core protein (subtype ayw), were 
purchased from Multiple Peptide Systems (San Diego, CA) or 
provided  by  Cytel  Corporation  (San Diego, CA).  Peptides 
representing amino- and carboxy-terminal truncations of HBcAg 
140-155, and a panel of peptides containing alanine substitutions 
scanning HBcAg 141-151, were produced by Chiton Mimotopes 
(Clayton, Australia).  Lyophilized  peptides were reconstituted at 10 
mg/ml in sterile distilled water with or without 10%  DMSO 
(Malinckrodt, Paris, KY). Recombinant (r)HBcAg was obtained 
from bacterial extracts ofEscherichia coli as previously  described (15). 
Tetanus toxoid protein was purchased from Connaught Laborato- 
ries (Swiftwater, PA). 
Recombinant Expression Vectors.  Recombinant vaccinia viruses 
expressing the HBV core (c-vac) region (ayw  subtype) and the con- 
trol wild-type vaccinia have been previously described (16). An- 
other construct (WTe) that produces the HBV precore  protein (H. J. 
Schlicht, unpublished observations) was also used. Stable transfec- 
rants that express HBcAg (ayw subtype) were produced by trans- 
fection of EBV-transformed B lymphoblastoid cell lines (B-LCL) 
with a panel of  EBV-based expressed vectors that contain the HBV 
core region as previously described (17). 
Stimulation of PBMC with Synthetic Peptides and rHBa  PBMC 
from patients and normal donors were separated  on FicoU-Hypaque 
density gradients (Sigma Chemical Co., St. Louis, MO), washed 
three times in HBSS (Gibco Laboratories, Grand Island, NY), 
resuspended in RPMI 1640 (Gibco Laboratories)  supplemented  with 
L-glutamine  (2 raM), penicillin  (50 U/ml), streptomycin  (50/~g/rrd), 
and Hepes (10 mM) containing 10% heat-inactivated human AB 
serum, and plated in a 24-well plate at 4  x  106 cells/well. The 
synthetic peptides, each at 10/~g/ml, were added to the cell cul- 
tures as follows:  mixture 1 (core  residues 1-20, 20-34, 28-47, 50-69, 
70-89, 61-80); mixture 2 (core residues 82-101, 100-119, 120-139, 
140-155, 155-169, 169-183); mixture 3 (precore residue 20-core 
residue 2, core residues 50-59, 117-131, 131-145, 111-125); mix- 
ture 4 (core residues 11-27, 91-110, 147-160, 162-176). rHBcAg 
(Biogen, Geneva, Switzerland) was added at 1/~g/ml to derive the 
benefit of a Th cell response within the culture during the first 
week of stimulation. At day 3, 1 ml of RPMI with 10% human 
AB serum and rII.,2 (Hoffman-La  Roche, Inc., Nutley, NY) at 10 
U/ml final  concentration was added in each well, and the cultured 
PBMC were tested for CTL activity on day 7. PBMC that dis- 
played cytolytic activity specific for one of the peptide mixtures 
used during the first week of stimulation were expanded by re- 
stimulation as described below. 
Generation of  HBV Core-s~cific CTL Lines.  Generation  of CTL 
line H1 from patient H.P., initially cultured with peptide mixture 
2 plus rHBcAg, was performed by weekly restimulation with 5 
x  10  s autologous PBMC irradiated (3,000 tad) in RPMI plus 10% 
human AB serum, rib2 (20 U/ml), and peptide mixture 2 (first 
restimulation), or with peptide 140-155 (10/~g/ml) for all subse- 
quent stimulations. CTL line E4 (from patient E.W.) and the CTL 
lines from four additional patients (V.T., H.F., Q.M., C.N.) were 
established by stimulating the PBMC with peptide 140-155 plus 
rHBcAg for the first week, with weekly restimulation thereafter 
with peptide 140-155 and rIL-2. The PBMC of the normal unin- 
fected controls were stimulated similarly  except that in selected in- 
stances tetanus toxoid was substituted for rHBc during the first 
week of stimulation to provide an alternate source of T cell help, 
since these individuals  had not been previously  exposed to HBcAg. 
Generation of  HBV-specific CTL Clones.  CTL clones  were gener- 
ated by limiting dilution at one cell/well in 96-well microtiter plates 
from an HBV-specific  CTL line, E4 (patient E.W.). After depletion 
of CD4 + T cells from the CTL line by incubation with a CD4- 
specific mAb (Becton Dickinson & Co., Mountain View, CA) plus 
complement, the cells were plated in the presence of PHA (Sigma 
Chemical  Co.) at 1/~g/ml, CD3-specific  mAb at 0.5/~g/ml (Coulter 
Immunology, Hialeah, FL), rib2 (20 U/ml), and irradiated (5,000 
tad) allogeneic PMBC (10S/well). HBV specific clones were re- 
stimulated in a 24-well plate with 10  s irradiated (9,000 tad) au- 
tologous transfectants expressing the HBV core region (described 
above), with 2  x  106 allogeneic irradiated (3,000 tad) PBMC 
feeder cells  per well, in RPM11640 containing 10% heat-inactivated 
FCS and Ib2 (20 U/m1). 
Target Cell Lines.  Autologous and allogeneic  EBV-transformed 
B-LCL were either purchased from The American Society for 
Histocompatibility and Immunogenetics (A.S.H.I.; Boston, MA) 
or established from our own pool of patients and normal donors 
as described (18). Line LB, HLA-Aw68.1  + (described in reference 
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erence 19, purchased from A.S.H.I., were used in selected experi- 
ments. The cells were maintained in RPMI with 10% (vol/vol) 
heat-inactivated FCS (Gibco Laboratories). Short-term lines of au- 
tologous PBMC blasts were produced by stimulating PBMC with 
PHA at 1 #g/ml in RPMI with 10% FCS, 10 U/ml rlL-2 for 7 d 
before use as target cells (see below). 
Cytotoxicity Assay.  Target  cells consisted either of: (a) autolo- 
gous  PHA-stimulated  blasts or  allogeneic HLA-matched and 
-mismatched B-LCL incubated overnight with synthetic peptides 
at varying concentrations between 0.001 and 10/~g/ml; (b) stable 
B-LCL transfectants described above; or (c) B-LCL infected with 
recombinant vaccinia  viruses. In selected  experiments (see Results) 
the target cells were labeled with SlCr for 1 h, followed by 1 h 
of incubation with synthetic peptides before the addition of effector 
cells. Vaccinia-infected  targets were prepared by infection of 106 
cells at 50 PFU/cell on a rocking plate at room temperature for 
1 h followed by a single wash and overnight incubation at 37~ 
Target cells were then labeled with 100 #Ci of SlCr (Amersham 
Corp., Arlington Heights, IL) for I h and washed three times with 
HBSS. Cytolytic activity was determined in a standard 4-h SlCr 
release assay using U-bottomed  96-well plates containing 5,000 
targets/well. Stimulated PBMC from patients and normal controls 
were tested at E.'T ratios between 60 and 100:1, whereas HBV core- 
specific CTL lines were tested at E.'T ratios between 4 and 50:1. 
All assays were performed in duplicate. Percent cytotoxicity was 
determined from the formula: 100x [(experimental  release -  spon- 
taneous release)/(maximum release -  spontaneous release)]. Max- 
imum release was determined by lysis  of targets by detergent (1% 
Triton X-100; Sigma  Chemical  Co.). Spontaneous  release was <25% 
of maximal release in all assays. 
Flow Cytornetry Analysis.  Cells  to be analyzed (0.5-1.0  x  106 
cells) were washed once in PBS and then incubated with a fluores- 
cent probe-conjugated  anti-CD4 and anti-CD8 mAb (Leu3a, Leu2a) 
and similarly labeled control antibody (Becton Dickinson & Co.). 
After a 30-min incubation at 4~  cells were washed in PBS with 
5% BSA and 0.1% sodium azide, and analyzed with a FACScan  | 
flow cytometer (Becton Dickinson & Co.). 
HLA Typing.  HLA typing of PBMC from patients and from 
normal donors was performed by microcytotoxicity using HLA 
typing trays purchased from One Lambda (Los Angeles, CA). The 
HLA haplotypes of six patients and nine uninfected normal con- 
trols used in this study are shown in Table 1. 
Results 
CTL  Activity  of PBMC  Stimulated  with  Peptide  Mix- 
tures.  PBMC from two patients (E.W., H.P.) with acute HBV 
infection were stimulated for 7 d with peptide mixtures, and 
then tested for cytolytic activity against autologous SlCr- 
labeled,  PHA-activated blasts prepulsed with the same pep- 
tide mixture or with media. Interestingly, responses  were 
observed to mixture 2 in both patients (Fig.  1).  Synthetic 
peptides contained in mixture 2 represent HBcAg sequences 
that have not been previously described  as recognition sites 
for HBV-specific human CTL, Accordingly, the remaining 
cells were restimulated for a second week with peptide mix- 
ture 2, and the antigenic specificity of the restimulated CTL 
line was established with autologous PHA-activated blast 
targets prepulsed with the individual peptides contained within 
the mixture. By this approach, peptide HBcAg 140-155 was 
Table  1.  HLA  Class I Haplotype of the HBV-infected Patients, 
and the HLA-A31- and Aw68-positive Normal Donors Included 
in  This Study 
Patient  HLA class I 
HBV patient 
Normal donor 
E.W.  A31,Aw68,B35,Cw3,Cw4 
H.P.  A2,Aw68,B35,Bw62,Cw3,Cw4 
V.T.  A25,A31,B7,B18 
H.F.  A31,Aw68,Bw61,Cw3 
Q.M.  Aw36,Aw68,B49,Bw62,Cwl 
V.P.  A24,Aw68,B35,Bw67 
C.N.  A24,Aw68,Bw60,Cw3 
a  A1,A31,B17,Bw60 
b  A2,A31,B27,B44,Cwl 
c  A3,A31,B7,B27 
d  A24,A31,B14,B35,Cw4 
e  A3,A31,B7 
f  A31,Aw68,B35,Bw60 
g  A3,Aw68,B7,B44,Cw7 
h  A1,Aw68,BS,B38,Cw7 
i  A11,Aw68,B35,B44,Cw4 
shown to be responsible for the CTL activity induced by mix- 
ture 2 for both of these patients (Fig.  2).  No cytotoxic ac- 
tivity was observed using unstimulated PBMC of  patient E.W. 
as effectors against autologous B-LCL fed with peptide HBcAg 
140-155 (data not shown), suggesting that specific CTL are 
present at low frequency in the peripheral blood during acute 
HBV infection. It is noteworthy that patient H.P. also dis- 
played a CTL response  to peptide mixture 4, and that pa- 
u) 
u 
N- 
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30 
20 
10 
Peptides 
[]  Mix  1 
￿9  Mix  2 
[]  Mix  3 
[]  MIx 4 
Peptides  Media  Peptides  Media 
Patient E. W. 
A31 ,Aw68,B35,Cw3,Cw4 
Patient H.P. 
A2,Aw68,B35,Bw62,Cw3,Cw4 
Figure  1.  Activation  of  HBV-specific  CTL by PBMC stimulation  with 
mixtures of synthetic  peptides. PBMC were stimulated  for 1 wk with 
mixtures of HBcAg peptides and tested for cytotoxic  activity  in a 4-h SlCr 
release assay  against autologous  targets prepulsed with the same stimula- 
tory mixture  or with media  only.  The E/T ratio  used  was 70:1 for patient 
E.W. and 100:1 for patient H.P. 
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Although the response to mixture 1 was transient and could 
not be further characterized, the response to mixture 4 was 
ultimately shown to be specific for core residues 18-27 and 
to be restricted by HLA-A2 (not shown), as we have previ- 
ously reported (12-14, 17), demonstrating that multiple, in- 
dependently restricted CTL responses to nonoverlapping CTL 
epitopes present on the same viral protein are readily detect- 
able during acute HBV infection. 
Generation and HLA  Restriction Analysis of HBc.Ag 140- 
155-specific CTL Lines and Clones.  HBcAg 140-155-specific 
CTL lines were generated by weekly stimulation of PBMC 
either with mixture 2 or with the active constituent peptide 
(core residues 140-155). Line E4 (patient E.W.) was started 
in the presence of rHBcAg and peptide HBcAg 140-155; line 
H1 (patient H.P.) was started in the presence of rHBc and 
mixture 2. 
After 4 wk of restimulation, the HLA class I restriction 
of CTL line H1 was tested by using several allogeneic B-LCL 
target cells that were partially matched with the effector cells 
at the HLA class  I loci but were completely HLA class II 
mismatched. The results, shown in Fig. 3, illustrate that the 
CTL activity was HLA-Aw68 restricted. The HBcAg 140-155- 
specific CTL line E4 was cloned at one cell per well in the 
Media 
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Figure 2.  Identification  of the target  peptide in mixture 2. PBMC, 
stimulated by peptide mixture 2 for the first week, were restimulated with 
the same mixture of peptides and tested for cytotoxic activity in a 4-h 
slCr release assay against slCr-labded autologous  target  cells prepulsed 
with the individual  peptides in the mixture. The E/T ratio used was 50:1 
for patient E.W. and 40:1 for patient H.P. 
w  _o 
<r 
'1o 
J=  u) 
A2,B35,C4 
Bwe2,C3 
Aw68 
Line H1 
Patiant H.P. 
D  Media 
￿9 HBcAg 140-155 
0  10  20  30  40  50  60 
%  Specific  Lysis 
Figure 3.  FILA restriction of the FIBcAg 140-155-specific  CTL response 
in patient H.P. A polydonal CTL line (H1) specific for HBcAg 140-155 
was incubated with s2Cr-labeled B-I.CL  target cells that were prepulsed 
with poptide HBcAg 140-155 or with media. All target cells were com- 
pletely mismatched at the level of class II and partially matched at the 
level of class I. The E/T ratio used was 4:1 in a 4-h 51Cr release assay. 
presence of anti-CD3,  PHA,  and aUogeneic PBL as feeder 
cells. After 2-3 wk, 15% of the seeded wells showed prolifer- 
ation, and the vowing cell populations were tested for specific 
lysis of autologous B-LCL preincubated with peptide core 
140-155.  Two  clones  (3Dll,  2D7)  that  displayed highly 
e~cient specific cytotoxic activity were selected for further 
analysis.  The clones were tested against autologous and al- 
logeneic B-LCL target cells partially matched with the effectors 
at the level of HLA class I and II alleles.  The cytolytic ac- 
tivity of clone 3Dll was found to be HLA-A31 restricted, 
and the cytolytic activity of clone 2I:)7, derived from the same 
patient, was HLA-Aw68 restricted (Fig. 4). Both clones dis- 
played the CD4-,  CD8 + phenotype by flow cytometry (not 
shown). 
These observations were confirmed and extended by anal- 
ysis of four additional HLA-A31- or Aw68-positive patients 
Cw3,Cw4,DR4 
B35,Cw4 
Q  DR4,DRw53,DQw3 
< 
￿9  o  A31,Cw3 
m  A31  ,DR4,DRw53  Jr 
Aw68 
All 
Figure 4. 
Patient E.. W. 
￿9 Clone  2D7 
[] Clone 3Dll 
I 
I  I 
I 
2'0  i0  '  d 
A % Specific Lysis 
1 
8o  10o 
HLA restriction of the HBcAg 140-155-specific  CTL response 
in patient E.W. Two HBcAg 140-155-speciilc  CTL tones (3Dll and 2D7) 
were established by limiting dilution and incubated with SlCr-hbeled au- 
tologous or allogeneic B-LCL target cells prepulsed with peptide 140-155 
or media. Allogeneic target cells were matched at the level of class I and 
class II with the effector cells. The E/T ratio used was 10:1 in a 4-h slCr 
rdease assay. Results are expressed as the difference between the percent 
slCr release observed with peptidg-pulsed targets and the percent slCr re- 
lease with media-pulsed target  cells (which was <3% in all cases). 
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these patients, HBcAg 140-155-specific CTL lines were gener- 
ated as described for line E4. Using partially HLA-matched 
aUogeneic target cells,  the CTL response was shown to be 
restricted by the HLA-A31 allele in patient V.T.; it was dearly 
HLA-Aw68 restricted in patient Q.M.  and probably Aw68 
restricted in patient C.N. (Table 2). The response in patient 
H.F.  was too weak to permit  further  analysis. 
~g  140-155-specific CTL Lines and Clones Can Lyse Target 
Cells That Express Endogenously Synthesized HBcAg.  Two 
polyclonal CTL lines (E4, H1) and two clones derived from 
line E4 (3Dll,  2D7) were tested for the ability to recognize 
endogenously synthesized nucleocapsid antigen by using au- 
tologous and allogeneic target  cells  that  had been infected 
with recombinant vaccinia viruses that direct the synthesis 
of the HBV core and precore proteins by the ceU. Line H1 
(patient H.P.) and line E4 (patient E.W.) were tested against 
endogenously synthesized core protein induced by a recom- 
binant vaccinia virus designated core~vac (Fig. 5). Clones 3Dll 
and 2D7 were tested against endogenously synthesized core 
and precore proteins induced by a recombinant vaccinia virus, 
designated  core-vac  and  WTe-vac,  respectively  (Fig.  6). 
Significant levels of specific cytolytic activity were detected 
in all cases (Figs. 5 and 6). Recognition of endogenously syn- 
thesized antigen by HBcAg 140-155  peptide-specific lines 
and clones demonstrates  that  the CTL epitope represented 
by the core sequence 140-155  is actually generated by the 
intracellular  processing of endogenously synthesized HBV 
core and precore proteins,  and that these CTL are likely primed 
in  vivo  during  HBV  infection.  The  latter  argument  is 
confirmed by our repeated failure to establish HBcAg 140-155- 
specific CTL lines from six HLA-A31-positive or from four 
HLA-Aw68-positive normal uninfected controls that we have 
studied thus  far (not  shown). 
The 11-mer HBcAg 141-151 Is the Minimum, Optimally Rec- 
ognized HLA A31- and Aw68-restricted Epitope within HBc.Ag 
140-155.  Carboxy- and amino-terminal truncations of the 
core 140-155 sequence were produced to map the CTL epi- 
topes that are restricted by HLA-A31 and Aw68 within this 
16-residue peptide (Table 3). Clone 3Dll, which is HLA A31 
Table  2.  HBcAg 140-155-specific Cytotoxicity of CTL Lines  from 
HLA-A31-  and Aw68-positive Patients with Acute HBV Infection 
Target 
Patient  HLA match  HBcAg 140-155  Media 
V.T.  A31  75  34 
H.F.  All  10  1 
Q.M.  Aw68  23  0 
C.N.  Aw68,A24  25  10 
PBMC stimulated with HBcAg 140-155 plus rHBcAg. Data represent 
percent SlCr release. 
Media 
HBcAg 140-155 / 
WT-vac  -7 
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Figure 5.  Recognition  of endogenously  synthesized  ~g  by HBcAg 
140-155-specific CTL lines E4 (HLA-A31 and Aw68 restricted) and H1 
(HLA-Aw68 restricted). CTL lines were incubated for 4 h with SlCr- 
labeled autologous  B-I.CL (line E4) and allogeneic  B-I/EL (line H1) matched 
at HLA-Aw68,  which had been prepulsed  with media or HBcAg 140-155 
peptide, or were infected with recombinant vaccinia viruses that express 
the HBV core protein. The E/T ratio used for line E4 was 10:1, for line 
HI was 20:1 for the peptide prepulsed target cells, and was 15:1 for the 
recombinant vaccinia-infected target calls. 
restricted,  and clone 2D7, which is HLA Aw68 restricted, 
were used to define the fine specificity of the CTL response. 
Autologous B-LCL were preincubated with the truncated pep- 
tides (10/~M) and used as targets with the two clones. We 
80 
a 
2O 
CTL  Clone  2D7 
AW68  Matched  y 
1  2  5  7  15 
CTL  Clone  3Dll 
A31  Matched  p  Target~ 
/~"  o Medla 
//_j  ￿9 .ecAg 1~1s5 
WT-Vac 
u  [] WTo-Var 
1  2  5  7  15 
Effector  :  Target  Cell  Ratio 
Figure 6.  HLA-restricted recognition of endogenously synthesized 
HBcAg  by CTL clones 2I)7 and 3Dll. Clones 2D7 and 3Dll were tested 
against HLA-Aw68-  and A31-matched aUogeneic  target cells, respecti~,ely. 
Targets were either preincubated with peptide HBcAg 140-155, or in- 
fected with recombinant vaccinia viruses coding for the core (Core.Vac) 
or the precore (WTe-Vac) proteins of HBV in a 4-h slCr release assay. 
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Peptides 
3Dll  2D7 
Residues  Sequence  A31  Aw68 
140-155  LSTLPETTVVRRRGRS  72  62 
140-154  LSTLPETTVVRRRGR  63  60 
140-153  LSTLPETTVVRRRG  75  66 
140-152  LSTLPETTVVRRR  77  69 
140-151  LSTLPETTVVRR  72  67 
140-150  LSTLPETTVVR  0  6 
141-155  STLPETTVVRRRGRS  81  66 
141-154  STLPETTVVRRRGR  79  67 
141-153  STLPETTVVRRRG  79  59 
141-152  STLPETTVVRRR  68  68 
141-151  STLPETTVVRR  69  66 
141-150  STLPETTVVR  20  52 
141-149  STLPETTVV  0  3 
142-155  TLPETTVVRRRGRS  8  63 
142-154  TLPETTVVRRRGR  18  54 
142-153  TLPETTVVRRRG  8  56 
142-152  TLPETTVVRRR  2  37 
142-151  TLPETTVVRR  47  60 
142-150  TLPETTVVR  0  0 
143-155  LPETTVVRRRGRS  0  0 
143-154  LPETTVVRRRGR  0  0 
143-153  LPETTVVRRRG  0  0 
143-152  LPETTVVRRR  0  2 
143-151  LPETTVVRR  0  0 
Autologous target  cells were  preincubated  with peptides at  10 #M; E/T ratio,  10:1. Lysis was of target  cells preincubated with media <2%  in 
all cases. Data represent percent  SlCr release. 
expected to identify two partially overlapping epitopes in pep- 
tide HBcAg 140-155. Surprisingly,  however, our data indi- 
cate that sequence 141-151 is the minimal, optimally recog- 
nized epitope for both restriction elements. Initial studies using 
the  truncated  peptides at  a single concentration  (Table  3) 
defined residue 151 (arginine)  as the putative carboxy terminus 
of the epitope recognized by both CTL clones. Interestingly, 
residue 150, which is also an arginine,  can also serve as the 
carboxy-terminal residue for both clones but only if residue 
141 (serine) serves as amino terminus.  Although serine 141 
appears to be the optimal amino-terminal residue of the epi- 
tope for both restriction elements,  residue 142 (threonine) 
can also serve as the amino terminus of the epitope for both 
clones if arginine 151 is the carboxy-terminal residue. In con- 
trast, only the HLA-Aw68-restricted clone (2D7) can use threo- 
nine 142 if the carboxy terminus of the peptide is extended 
beyond residue 151. The chemical similarity of the two amino- 
terminal residues (serine 141, threonine 142) and the identity 
of the two carboxy-terminal residues (arginine  150, 151) prob- 
ably contribute  to these observations. 
To precisely define the boundaries of the epitope(s), a dose 
titration analysis was conducted in which the two CTL clones 
were incubated with allogeneic HLA-A31- and HLA-Aw68- 
positive  target  cells  preincubated  with  peptides  140-155, 
140-153, 140-151, 141-151,  141-150, 141-152, and 142-151 
at different molar concentrations  ranging  from  10 -3  tO  10 
/~M. From these studies it is clear that core residues 141-151 
represent the minimal optimally recognized epitope recog- 
nized by both of the CTL clones (Fig.  7), suggesting that 
both HLA alleles bind and present exactly the same peptide 
to their corresponding CTL. The availability of HLA-Aw68.1- 
and HLA-Aw68.2-positive cell lines  permitted us to define 
the HLA-Aw68 subtype responsible for presentation  of HBcAg 
141-151 to clone 2D7. HLA Aw68.1-positive target cells pulsed 
with  HBcAg 141-151  (1 /zM)  were efficiently lysed (39% 
specific SlCr release) by clone 2D7 at an E/T ratio of 10:1, 
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Figure 7.  Identification of the shortest optimally recognized sequence 
in HBcAg  140-155 for each HLA restriction element. Clone 3Dll was 
tested against allogeneic SlCr-labeled A31-positive target cells and clone 
2D7 against allogeneic slCr-labeled Aw68-positive target cells prepulsed 
for 1 h with various peptides at concentrations  ranging between 0.001 
and 10/~M. Target cells were incubated in presence of peptides at 37~ 
for 1 h and subsequently diluted 20-fold in RPMI 1640 containing 10% 
FCS and added to the effector cells for 4 h at an E/T ratio  of 10:1. 
in contrast to HLA-Aw68.2-positive targets, which displayed 
no specific lysis under the same conditions  (not shown). 
Identification of Critical Residues Involved in Presentation and 
Recognition of  HBcAg 141-151.  To define the residues within 
HBcAg 141-151 that interact with the HLA-A31 and Aw68 
molecules and that are recognized by the CTL receptors of 
clones 3Dll and 2D7, respectively, a series of peptides con- 
taining  individual  alanine  substitutions  at  each  residue 
(A141-A151) were produced. AUogeneic  HLA-A31- and HLA- 
Aw68-matched  target cells were pulsed with each peptide 
at multiple concentrations  between 0.001 and 10/~M and 
used in a 4-h SlCr release assay with clones 3Dll and 2D7 
at an E:T ratio of 10:1. Comparison of the dose-response  curves 
for each substituted peptide revealed a hierarchy that is illus- 
trated in Fig. 8, with the results obtained at a single peptide 
concentration (1 #M) for clarity. As shown in Fig.  8,  the 
two clones displayed similar, but not identical, peptide rec- 
ognition profiles. Interestingly, substitutions  of leucine 143 
and arginine  151  either reduced or nearly abolished CTL- 
mediated killing by both clones. In contrast to these shared 
substitutions,  threonine 146 and threonine 147 substitutions 
almost completely abolished CTL-mediated killing by clone 
2D7, but they had no effect on clone 3Dll. On the contrary, 
substitution of glutamic acid 145, valine 149, and arginine 
150 almost completely abolished recognition by 3Dll but 
had no effect on 2D7. Although it is clear that these residues 
are involved in peptide interaction with either the HLA class 
I restriction elements or with the TCRs of the corresponding 
CTL clones, the fact that leucine 143 and arginine  151 ap- 
pear to be important for both HLA-A31- and the HLA-Aw68- 
restricted responses suggests to us that these residues may 
mediate the binding of HBcAg 141-151 to both HLA alleles 
(agretope), while threonine 146 and 147 may represent residues 
that interact with the TCR of clone 2D7 (epitope), whereas 
glutamic acid 145, valine 149, and arginine 150 might con- 
tribute to the epitope  recognized by the 3Dll  TCR. 
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Recognition of HBcAg 141-151 peptides containing  alanine  Figure  8. 
substitutions at each residue. Identification of critical residues involved 
in presentation and recognition of HBcAg 141-151. Clone 3Dll was tested 
against SlCr-labeled allogeneic A31-positive target cells, and clone 2D7 
against allogeneic slCr-labeled Aw68-positive target cells that had been 
prepulsed for 1 h with varying concentrations (0.001-10 #M) of HBcAg 
141-151 or with a panel of modified peptides in which alanine was sub- 
stituted at each position. Target cells were incubated in presence of pep- 
tides at 37~  for I h and subsequently diluted 20-fold in RPMI 1640 con- 
taining 10% FCS and added to the effector cells for 4 h at an E/T ratio 
of 8:1. Representative results obtained at 1 t~M peptide concentration are 
shown. 
To distinguish between HBcAg 141-151 residues that in- 
teract with the HLA-A31 and Aw68 molecules and those 
residues that are seen by the CTL receptor in clones 3Dll 
and 2D7, we examined the ability of alanine-substituted pep- 
tides (100/xM) to prevent the binding of the native HBcAg 
141-151 peptide (0.05 and 0.01/~M,  respectively) to HLA- 
A31- and HLA-Aw68-positive target  cells (Fig. 9). 
Our results demonstrate that alanine substitutions  of glu- 
tamic acid 145 and valine 149 effectively  block CTL recogni- 
tion of HBcAg 141-151 by HLA-A31-restricted clone 3Dll, 
indicating that they probably represent TCR binding residues 
(epitope). In contrast,  peptides containing alanine substitu- 
tions  at residues leucine 143 and arginine  150 and 151  do 
not block the binding of HBcAg 141-151 to the HLA-A31 
molecule, suggesting that some or all of these three residues 
are probably involved in the interaction of HBcAg 141-151 
with HLA-A31. The results are particularly convincing for 
positions  150  and  151  because the corresponding alanine- 
substituted  peptides do not sensitize the target cells to lysis 
by clone 3Dll at the high concentrations  used for competi- 
tion  in  this  experiment.  However,  because  the  alanine 
143-substituted peptide itself was recognized at the high con- 
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Figure 9.  Competitive inhibition  binding  of HBcAg 141-151 to HLA- 
Aw68 and A31. Identification of residues within HBcAg 141-151 respon- 
sible for interaction with HLA-A31 and HLA-Aw68, and with the CTL 
receptors in clones 2D7 and 3Dll. Peptides containing alanine substitu- 
tions at the indicated positions (100 ttM) were added to HLA-Aw68- or 
HLA-A31-positive target cells for 10 rain, after which HBcAg  141-151 
was added as a target peptide at 0.01 or 0.05/~M, respectively. 1 h later 
the target cells  were diluted 20-fold  in complete media and the corresponding 
CTL clones were added at an E/T ratio of 10:1 in a 4-h slCr release assay. 
Results are expressed as percent inhibition  of the HBcAg 141-151-specific 
lysis observed in the absence of competitor peptide. 
centrations required for this experiment, additional experi- 
ments were performed using a peptide with a nonconserva- 
rive substitution (glutamic acid) at position 143. This peptide 
did not sensitize target cells even at high concentrations and 
it did not compete with the unsubstituted HBcAg 141-151 
when it was used at 100-fold molar excess. Thus, the data 
suggest that leucine 143 and arginine 150 and 151 are prob- 
ably HLA-A31  contact residues. 
For the HLA-Aw68-restricted CTL clone 2D7, alanine sub- 
stitution of threonine 146 and threonine 147 effectively block 
CTL recognition of HBcAg 141-151, indicating that these 
residues probably represent a TCR residue (epitope). On the 
other  hand,  peptides containing  alanine  substitutions  at 
residues leucine 143 and arginine 151 do not block the binding 
of HBcAg  141-151 to the HLA-Aw68  molecule, even at 
10,000-fold molar excess (concentrations that are entirely non- 
sensitizing for lysis by done 2D7). These data strongly sug- 
gest that both of these residues are necessary for interaction 
of HBcAg 141-151 with HLA-Aw68. 
Discussion 
In the present study we have identified a new CTL epi- 
tope in the nudeocapsid protein of the HBV, corresponding 
to HBcAg residues 141-151, by synthetic peptide stimulation 
of PBL from patients with acute viral hepatitis. We have shown 
that this epitope is generated by the cellular processing of 
endogenously synthesized HBV core and precore proteins, 
and that the CTL response to this single 11-residue minimal 
epitope is restricted by two different HLA molecules, HLA- 
A31 and HLA-Aw68. Finally, we have defined, at least par- 
tially, the agretopic and epitopic residues in HBcAg 141-151 
that are seen by two independently restricted CTL dones, 
and by so doing we have tentatively identified a common, 
allele-specific binding motif for HLA-A31  and Aw68. 
As we have reported previously (12-14,  17), we used syn- 
thetic peptides to expand the quantitatively limited, periph- 
eral blood CD8-positive HBV antigen-specific  cytotoxic T 
cell population in our patients. This strategy is necessary be- 
cause HBV does not readily infect human cell lines in vitro 
and because our panel of stable HBV transfectants  (17) ap- 
parently do not express sufficient amounts of endogenously 
processed antigen on the cell surface for efficient in vitro sec- 
ondary induction of an HBV antigen-specific, class I-restricted 
peripheral blood CTL response in the HBV-infected patients 
we have studied thus far. In contrast, CTL stimulation with 
synthetic peptides is a powerful strategy to expand antigen- 
specific CTL populations that have been primed in vivo since 
we have shown, here and elsewhere (14, 17), that the peptide- 
stimulated CTL can efficiently recognize targets that express 
endogenous antigen. It is interesting that the stable transfec- 
tants can be very effectively  used to select, expand, and maintain 
CTL that preferentially recognize endogenously synthesized 
antigen from the peptide-stimulated CTL population despite 
their inability  to  expand  the  same  antigen-specific  CTL 
without prior stimulation by the synthetic peptides. This may 
reflect the requirement for a higher epitope density for in- 
duction of a CTL response than for its maintenance, as pre- 
viously described (14, 17). Nonetheless, the use of these trans- 
fectants for this purpose is important because it selects for 
the  expansion  of  CTL  populations  that  recognize  en- 
dogenously synthesized epitopes rather than those subpopu- 
lations of CTL that only recognize the peptide used for the 
initial expansion. 
It is noteworthy that the current stimulation strategy has 
permitted us to detect a CTL response to two independent 
epitopes in patient H.P., who displayed a response to the HLA- 
A2-restricted HBcAg 18-27 epitope that we have previously 
reported (12-14,  17) and to the HLA-Aw68-restricted epi- 
tope HBcAg 141-151 reported herein. Furthermore, patient 
E.W. yielded two independent CTL clones whose antigenic 
fine specificity differed according to the HLA allele that re- 
stricted the response (glutamic acid 145 and valine 149 for 
the HLA-A31-restricted done, and the two threonine residues 
at positions 146 and 147 for the clone restricted by HLA- 
Aw68). These data,  and others not presented in this study 
(F. V. Chisari et al., unpublished observations),  suggest that 
the CTL response to HBV in humans is both polyvalent and 
muhispecific, presumably to afford efficient protection from 
this serious viral infection. 
Another interesting result is the efficient CTL recogni- 
tion of target ceils expressing endogenously synthesized core 
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the presence of a 29-residue amino-terminal signal sequence 
in the precore protein that directs it to the endoplasmic retic- 
ulum where  19 amino-terminal residues  and 34 carboxy- 
terminal residues  (residues  149-183)  are removed and the 
product is secreted via the Golgi apparatus into the serum 
as HBeAg. In contrast, the core protein lacks the signal se- 
quence and is targeted principally to the nucleus by a series 
of arginine-rich localization signals at its carboxy terminus 
(20); one of which (residues 145-156) also plays a critical role 
in viral RNA encapsidation (21). It is interesting that residues 
141-151 are involved in all of these important events in the 
virus life cycle. The significance of this observation is not 
known at present. However, the CTL response to this epi- 
tope could be especially effective at viral clearance because 
in addition to destroying HBV-infected cells, CTL-resistant 
"escape" mutants at this epitope would probably be nonviable. 
The current data indicate that, despite their different intra- 
cellular tra~cking pathways,  the core and precore proteins 
appear to intersect either at the level of proteolytic processing 
in the cytoplasm or at the level of MHC binding within the 
endoplasmic reticulum since target cells that synthesize ei- 
ther protein are equally recognized by HBcAg 18-27 (14) 
and HBcAg 141-151-specific CTL (Fig.  6). 
Relatively few antigenic determinants have been described 
that are broadly presented by multiple MHC molecules. In 
most instances the responses have been class II restricted (22, 
23),  although a  murine CTL epitope in  HIV-1  envelope 
glycoprotein has been recently described that can be presented 
by at least four different class I MHC molecules from in- 
dependent haplotypes (24).  However,  at  the human class 
I-restricted CTL level, broadly restricted responses have been 
described only for partially overlapping epitopes (25), or for 
antigens in which the minimal CTL epitope has not been 
precisely determined (26). To our knowledge, therefore, this 
is the first report that a single, precisely defined CTL epitope 
generated by the intracellular processing of an endogenously 
synthesized protein effectively induces a specific  CTL response 
that is restricted by two independent HLA class I alleles in 
vivo in humans. 
Insight into the molecular basis for this event can be gained 
by comparing the structural and chemical properties of the 
antigen-binding pockets in the HLA molecule with the results 
of our alanine  substitution experiments. The polymorphic 
HLA class I protein is characterized  by 20 highly variable 
residues, 16 of which are thought to contribute to formation 
of at least two pockets that have been identified in the an- 
tigen binding groove of the HLA-A2 and HLA-Aw68 mole- 
cules (27-30). These pockets are presumed to represent the 
binding sites of critical anchor residues within antigen pep- 
tides that mediate their binding to the HLA class I molecule. 
Structural analysis reveals that one of these pockets is formed 
by hydrophobic residues at positions 24, 26, 34, and 67 of 
the class I heavy chain plus a highly variable residue at posi- 
tion 45 (30). Comparative DNA sequence analysis reveals that 
this pocket should be present in all HLA-A molecules, except 
perhaps HLA-A1 (31). The existence of a hydrophobic pocket 
in the HLA-A2 protein is compatible with recent observa- 
tions that leucine and other hydrophobic amino acids located 
at position 2 represent a critical anchor residue for antigenic 
nonamer and decamer peptides that can be eluted from the 
HLA-A2.1 binding groove (32, 33). It is also consistent with 
our  previous identification of leucine at  position 2  in  a 
10-amino acid  HBcAg-derived sequence  (HBcAg  18-27) 
(FLPSDFFPSV) that is a major, HLA-A2-restricted CTL epi- 
topes in patients with acute viral hepatitis (12). 
It is important to note that leucine 143 is present as res- 
idue 3 of the HLA-A31- and HLA-Aw68-restricted CTL epi- 
tope described in the current report (STLPETTWRR). This 
observation raises the possibility that leucine 143 may con- 
tribute, as an anchor residue, to the binding of this peptide 
to both restriction elements. Indeed, our experimental results 
(Figs. 8 and 9) suggest that this is true although the relative 
importance of this residue in binding to the HLA-A31 and 
Aw68 molecules may be somewhat different. 
Structural analysis of the HLA-Aw68 protein reveals the 
presence of a prominent negatively charged pocket, defined 
by an aspartic acid in position 74 in both HLA-Aw68.1 and 
68.2 subtypes, plus two residues at positions 97 and 116, which 
differ between the two subtypes (Aw-68.1, methionine and 
aspartic;  Aw68.2, arginine and tyrosine). Because of these 
differences, positively charged residues like arginine, in anti- 
genic peptides, have access to the 74 pocket in HLA-Aw68.1 
but not in Aw68.2 (31). Comparative DNA sequence anal- 
ysis reveals that residues  74,  97,  and 116 are all conserved 
in HLA-Aw68, A29, A31, A32, and A33 molecules but not 
in other class I alleles. 
Since a positively charged carboxy-terminal residue (argi- 
nine 151) is required for recognition of the current epitope 
by both HLA-Aw68-  and A31-restricted  CTL (Table 3 and 
Figs. 7 and 8), it is possible that it represents a second impor- 
tant anchor residue required for peptide interaction with both 
of these HLA molecules. This is supported by the alanine 
substitution studies, which demonstrate that arginine 151 is 
critical for presentation of HBcAg 141-151 to both CTL clones 
(Fig.  8) but that it does not behave as an epitopic residue 
in blocking studies illustrated in Fig. 9, suggesting that it 
is probably involved in interaction with the HLA class I mol- 
ecules. The data also suggest that arginine 150 may bind to 
HLA-A31 but not to Aw68 (Figs. 8 and 9). It is pertinent 
to point out, at this point, that an arginine has also been 
suggested to be the anchor residue for the 74 pocket of HLA- 
Aw68 for an influenza CTL epitope (19). Furthermore, the 
inability  of HLA-Aw68.2-positive target  cells  to  present 
HBcAg 141-151 to clone 2D7, while HLA-Aw68.1-positive 
target cells are fully functional, supports our belief that the 
carboxy-terminal arginine anchors HBcAg 141-151 to the 74 
pocket of the HLA-Aw68.1  molecule. 
As mentioned above, our data suggest that the epitopic 
residues within HBcAg 141-151 that interact with the CTL 
receptor are different for the two clones we have studied. The 
HLA-A31-restricted CTL clone 3Dll recognizes glutamic acid 
145 and valine 149 while the HLA-Aw68-restricted CTL clone 
2D7 recognizes the two threonine residues at positions 146 
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A31- and Aw68-restricted,  HBcAg-specific CTL clones in 
the future to assess the degree to which the CTL repertoire 
varies  with  respect  to  recognition  of this  HBV-encoded 
antigen. 
Finally, the identification of this new CTL epitope in the 
HBV nucleocapsid protein is relevant to HBV immunobi- 
ology and pathogenesis for several reasons. 
First, it expands our knowledge of the HBV-specific CTL 
repertoire to a new domain within the viral nucleocapsid pro- 
tein  and to two new HLA class  I  restriction  elements. 
Second, it demonstrates, for the first time, that the HBV- 
specific CTL response during acute viral hepatitis extends to 
multiple viral epitopes and different restriction elements; i.e., 
it is polyclonal, multispecific,  and polymorphically restricted, 
thereby affording enhanced protection for the host against 
a pathogen that is as dangerous and as prone to mutate as HBV. 
Third, it demonstrates that the HBV core and precore pro- 
teins are equally good targets of a nucleocapsid-specific CTL 
response to a shared epitope such as HBcAg 141-151,  as we 
have previously demonstrated for HBcAg 18-27 (14).  This 
implies that viruses containing mutations that affect only one 
of these proteins, such as the weU-described precore stop codon 
mutation  that  blocks precore  protein  translation  without 
affecting the core protein (34, 35), probably do not represent 
CTL escape mutants, since cells infected by the mutant viruses 
should still produce the HBcAg 141-151 epitope and be dim- 
inated by the CTL.  This further implies that factors other 
than  CTL-imposed selection pressure are probably respon- 
sible for emergence of the precore codon 28 mutants  that 
appear to be more virulent than wild-type forms of HBV (35). 
Fourth, it focuses our attention on a functionally impor- 
tant domain within the HBV nudeocapsid region that is in- 
volved not only in nuclear localization of HBcAg (20) but 
also in viral RNA encapsidation  (21),  and also in cleavage 
of the precore protein to produce HBeAg (36). Empirically, 
generation of a CTL response to this particular domain would 
afford a double benefit to the host, first, by destroying the 
infected cells and, second, by selecting for nonviable mutants 
since at least two of these functions are known to be impor- 
tant  in  the viral life cycle. 
Finally, if we can demonstrate that chronically HBV-infected 
HLA-A31-  and  Aw68-positive patients  respond  poorly to 
HBcAg 141-151,  as we have demonstrated for the HLA-A2- 
restricted response to HBcAg 18-27 (13),  it may represent 
a second potential target for future CTl.,based, immunother- 
apeutic strategies designed to terminate chronic HBV infec- 
tion. Since such strategies are HLA haplotype dependent, the 
known world-wide prevalence of the HLA-A2, HLA-A31, 
and Aw68 alleles (37) suggests that the successful induction 
of a CTL response to HBcAg 18-27 could benefit •45% 
of chronically infected patients,  and that  another  15-20% 
could benefit from induction of a therapeutic HBcAg 141-151- 
specific  CTL response. 
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Note added in proof'. While this manuscript was under review, Guo et al. and Silver et al. (38, 39) demon- 
strated, by structural analysis, that the HLA-Aw68.1 molecule binds peptides containing a threonine res- 
idue in position 2, a hydrophobic residue (such as leucine) in position 3, and an arginine residue at the 
carboxy terminus. Since HBcAg 141-151 contains this precise motif, and since we had not identified threo- 
nine 142 as an important  binding  residue for HLA-Aw68, or for HLA-A31, in our alanine substitution 
studies (Fig. 8), we examined the ability of a peptide containing  a nonconservative tryptophan  residue 
at this position (T142W) to prime target cells for recognition by clones 2D7 (HLA-Aw68 restricted) and 
3Dll (HLA-A31) restricted). In a peptide dose titration  experiment we recently determined that peptide 
T142W was recognized 100-1,000-fold less efficiently by clones 2D7 and 3Dll in comparison with the 
native peptide (not shown).  These new findings are compatible with the recently published structural 
data mentioned above (38, 39), and they suggest that threonine in position 2 may also serve as an anchor 
residue for the binding  of immunogenic  peptides to HLA-A31 as well. 
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